Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rapid Micro Biosystems, Inc. (NASDAQ: RPID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As an emerging growth company listed on Nasdaq, Rapid Micro Biosystems reports material events, financial results, and financing arrangements through forms such as Form 8-K, as well as its periodic reports on Forms 10-Q and 10-K.
Recent 8-K filings referenced in company communications include results of operations and financial condition for specific quarters and details of a Loan and Security Agreement with Trinity Capital Inc. These filings describe a five-year, $45 million term loan facility, the structure of tranches, interest terms, security interests in company assets, warrant issuance to lenders, and customary covenants and events of default. Other 8-K items incorporate press releases announcing quarterly financial results, including product revenue, service revenue, recurring revenue, and system placement and validation activity.
Through this page, users can review quarterly reports (Form 10-Q), which typically contain more detailed financial statements, segment information, and risk factor updates, and annual reports (Form 10-K), which provide a comprehensive overview of the company’s business, including its Growth Direct system, microbial quality control focus, and role in pharmaceutical manufacturing quality control. Filings related to debt facilities, warrant issuance, and other securities transactions are also accessible.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as revenue composition, recurring revenue trends, capital structure changes, covenant terms, and material events. Users interested in Rapid Micro Biosystems’ regulatory history, financial condition, and obligations under its loan facility can use this page to follow new filings as they are made available through EDGAR.
Rapid Micro Biosystems chief financial officer Sean M. Wirtjes reported an automatic sale of shares to cover taxes tied to equity compensation. On February 9, 2026, he sold 6,027 shares of Class A common stock at $3.7827 per share in a transaction coded as a sale. The filing states this sale was made automatically to satisfy tax obligations arising from the vesting of restricted stock units. After this transaction, Wirtjes directly owned 483,928 shares of Rapid Micro Biosystems Class A common stock.
Rapid Micro Biosystems, Inc. President and CEO Robert G. Spignesi Jr. reported an automatic sale of Class A common stock. On 02/09/2026, he sold 12,840 shares at $3.7827 per share to cover tax obligations related to vesting restricted stock units. After this transaction, he beneficially owned 962,097 shares directly.
A holder of RPID Class A common stock has filed a notice of proposed sale under Rule 144. The filing covers an intended sale of 6,027 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/09/2026 and an aggregate market value of $22,798.33.
The seller acquired these 6,027 shares on 02/06/2026 via restricted stock vesting from the issuer as compensation, and represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder in RPID has filed a notice of proposed sale under Rule 144 for 12,840 shares of Class A stock. These shares were acquired through restricted stock vesting on 02/06/2026 as compensation. The planned sale, valued at $48,569.87 based on market prices, is expected around 02/09/2026 through Fidelity Brokerage Services LLC on the NASDAQ. The filing notes that 39,823,026 shares of this class were outstanding, providing context for the size of the planned sale.
A shareholder of RPID filed a notice of intent to sell 4,610 shares of Class A stock under Rule 144. The planned sale, valued at $17,438.25, is to be executed through Fidelity Brokerage Services LLC on the NASDAQ around February 9, 2026. These shares were acquired on February 6, 2026 through restricted stock vesting as compensation from the issuer, indicating they are recently vested equity awards being sold into the market.
Rapid Micro Biosystems, Inc. insider entities reported a share sale and updated holdings. On February 4, 2026, Longitude Prime Fund, L.P. reported an indirect sale of 49,000 shares of Class A common stock at $3.8794 per share, leaving it with no reported shares afterward.
Separately, Longitude Venture Partners II, L.P. reported continued indirect beneficial ownership of 4,029,245 shares of Class A common stock. General partner entities and individuals associated with these funds may be deemed to share voting and dispositive power but expressly disclaim beneficial ownership beyond their pecuniary interests.
Rapid Micro Biosystems, Inc. (RPID)$0.05 per share on a cashless basis, with 7,739 shares withheld to cover the exercise price.
After these transactions, Longitude Venture Partners II, L.P. held 4,029,245 Class A shares indirectly. Separate from this, Longitude Prime Fund, L.P. sold 46,000, 27,500 and 27,500 Class A shares on
The filing explains that Longitude Capital Partners II, LLC and Longitude Prime Partners, LLC are general partners of the respective funds, and individuals Patrick G. Enright and Juliet Tammenoms Bakker are managing members, all disclaiming beneficial ownership beyond their pecuniary interests.
Rapid Micro Biosystems, Inc. reported that it has released a press release with preliminary, unaudited revenue results and selected business highlights for the fourth quarter and full year ended December 31, 2025. The update is being shared through a furnished Form 8-K, which means the revenue information and commentary are provided for investors but are not deemed filed for liability purposes under certain Exchange Act provisions. The press release, attached as an exhibit, offers an early view of how the company’s business performed in late 2025 ahead of its formal financial statements.
Rapid Micro Biosystems, Inc. (RPID) director Kirk Malloy reported a charitable gift of 40,000 shares of the company’s Class A common stock on 11/14/2025. The transaction was coded as a gift at a reported price of $0, reflecting that it was a non-sale transfer to a non-profit charitable organization.
After this transaction, Malloy beneficially owns 28,600 shares directly and an additional 10,000 shares indirectly through a family trust in which he shares investment power and where he and/or immediate family members are beneficiaries.
Rapid Micro Biosystems (RPID) reported Q3 2025 results and added new debt capacity. Revenue was $7.8 million, essentially flat year over year ($7.6 million). Product revenue was $5.2 million and service revenue $2.6 million. The company recorded a net loss of $11.5 million, similar to the prior year’s $11.3 million, as operating expenses and cost of sales remained elevated.
For the first nine months, revenue rose to $22.3 million from $19.8 million, while net loss narrowed to $34.6 million from $37.2 million. Cash and cash equivalents were $18.9 million and short‑term investments $22.3 million as of September 30, 2025. Deferred revenue stood at $5.1 million, supporting future service activity.
On August 8, 2025, the company entered a loan and security agreement of up to $45.0 million with Trinity Capital, drawing $20.0 million initially at a minimum interest rate of 11.0% (initially 11.5%). In connection, RPID issued warrants for 179,104 Class A shares at a $3.35 exercise price; a warrant liability of $0.36 million was recorded. Operating cash outflow was $27.8 million for the nine‑month period. As of October 31, 2025, Class A shares outstanding were 39,823,026 and Class B were 4,499,529.